What do you need to ask during the vetting and selection process to ensure your clinical or commercial program won’t be derailed by a quality-related problem?
Drug development companies (sponsors) may assume a commitment to quality is inherent in the operations of every contract development and manufacturing organization (CDMO), simply because product quality is essential for ensuring patient safety. Certainly, every CDMO professes its commitment to quality. So, in evaluating potential partners to manufacture a drug or biologic, how can one accurately assess the CDMO’s commitment to quality?
The answer involves conducting a thorough on-site quality audit, asking the right questions, and requesting detailed information. The answers, data, and documents provided will reveal—by what they contain and what they omit—whether or not the CDMO has a strong quality management system and quality culture.
A CDMO should welcome an on-site audit of its facilities and operations as part of the vetting process. Reluctance to have an audit is a red flag that something is wrong.
If the sponsor company is a small start-up or has limited auditing experience, an experienced firm may be hired to conduct the inspection, ideally with the participation of a member of the sponsor’s own team.
If the sponsor conducts the inspection, a great way to ensure all the bases are covered is to follow the FDA quality system inspection technique that the agency publishes for use by its own inspectors (1). The FDA guide describes how inspections should be performed on six systems—those related to quality, facilities and equipment, materials, production, packaging and labeling, and laboratory controls. The approach described should be adopted, and the following key questions should be asked and certain information requested.
Read the article in the Partnerships for Outsourcing eBook.
BioPharm International®
Partnerships for Outsourcing eBook
May 2024
Pages: 12-16
When referring to this article, please cite it as Szymanska, A. How to Evaluate a CDMO's Commitment to Quality. BioPharm International Partnerships for Outsourcing eBook, May 2024.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.